Benjamin Creelan

8PUBLICATIONS
45CO-AUTHORS
Molecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 09, 2025
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy.

Chao Wang, Xiaoqing Yu, Jamie K Teer

|Oct 08, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

Xiuning Le, Jyoti D Patel, Elaine Shum

|Sep 30, 2024
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.

Tyler J Alban, Nadeem Riaz, Prerana Parthasarathy

|Mar 07, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.

Alberto A Chiappori, Ben Creelan, Tawee Tanvetyanon

|Aug 13, 2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

Benjamin C Creelan, Chao Wang, Jamie K Teer

|Oct 05, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.

Benjamin C Creelan, Tammie C Yeh, Sang-We Kim

Pageof 2

Frequent Collaborators

2 joint publications

James J Saller

2 joint publications

Jose R Conejo-Garcia

2 joint publications

Theresa A Boyle

2 joint publications

John M Koomen